Apontis Pharma AG Sustainability Profile
Apontis Pharma AG, a prominent player in the pharmaceutical industry, is headquartered in Düsseldorf, Germany. Founded in 2016, the company has quickly established itself as a leader in developing innovative therapies for patients with complex health conditions, particularly in the fields of neurology and oncology. Apontis Pharma focuses on creating unique, patient-centric solutions that address unmet medical needs, leveraging advanced drug delivery systems and proprietary technologies. With a commitment to enhancing treatment outcomes, the company has achieved significant milestones, including strategic partnerships and successful clinical trials. Recognised for its dedication to research and development, Apontis Pharma AG continues to strengthen its market position, aiming to improve the lives of patients across Europe and beyond.
DitchCarbon Score
How does Apontis Pharma AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Apontis Pharma AG's score of 38 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Apontis Pharma AG, headquartered in Germany, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Zentiva Group, a.s., which influences its climate commitments and performance metrics. As of now, Apontis Pharma AG has not publicly disclosed any reduction targets or specific climate initiatives. However, it is important to note that the climate strategies and targets may be informed by the practices of its parent company, Zentiva Group, a.s., which operates at a cascade level of 3 in terms of sustainability initiatives. While Apontis Pharma AG has not set its own Science-Based Targets (SBTi) or other reduction commitments, the overarching corporate family relationship may provide a framework for future climate action. The absence of specific emissions data and reduction initiatives highlights a potential area for development in Apontis Pharma AG's sustainability strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2024 | |
|---|---|---|
| Scope 1 | 305,480,000 | 0,000 |
| Scope 2 | 79,081,000 | 0,000 |
| Scope 3 | - | 00,000 |
How Carbon Intensive is Apontis Pharma AG's Industry?
How Carbon Intensive is Apontis Pharma AG's Location?
Apontis Pharma AG's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "End-of-Life Treatment of Sold Products" being the largest emissions source at 1818% of Scope 3 emissions.
Top Scope 3 Categories
Apontis Pharma AG's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Apontis Pharma AG has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.